3-Alkylxanthines, processes for their preparation and compositions for use in the treatment of chronic obstructive airway disease and cardiac disease
申请人:Aktiebolaget DRACO
公开号:EP0010531A1
公开(公告)日:1980-04-30
3-Alkylxanthines characterized by the formula
wherein R1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobuty, cyclopentyl or cyclohexylmethyl, and R2 is hydrogen or methyl, provided that R2 is methyl when R1 is n-propyl, n-butyl or isobutyl, or a physiologically acceptable salt thereof, for example the compound 3-cyclopetnyl-3, 7-dihydro-1H-purine-2, 6-dione, have activity against chronic obstructive airway disease or cardiac disease. These compounds are produced by several methods, exemplified by the following one: reacting a compound of the formula
with a compound of the formula
wherein R1 and R2 have the definition given above and X is -COOH,-CONH2 or-OC-O-CO-R2 and, if necessary, submitting the obtained product to dehydration. The starting compounds wherein R' is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyc lohexylmethyl are not previously described in teh literature They are prepared by reacting a compound of the formula R1NHCONH2 with cyanoacetic acid, cyclising the producec 1-cyanoycetyl-3-R1urea with alkali, nitrosing the so produced 1-R'-6-aminouracil with HNO2 and reducing the so produced 1-R1-5-nitroso-6-aminouracil with H2//PtO2.
3-烷基黄嘌呤,其特征在于
其中 R1 为正丙基、正丁基、异丁基、正戊基、2-甲基丁基、3-甲基丁基、2,2-二甲基丙基、环丙基、环丁基、环戊基或环己基甲基,R2 为氢或甲基,但当 R1 为正丙基时,R2 为甲基、例如,3-环乙炔基-3,7-二氢-1H-嘌呤-2,6-二酮化合物具有防治慢性阻塞性气道疾病或心脏病的活性。这些化合物可通过以下几种方法制得,例如
与式
其中 R1 和 R2 具有上述定义,X 为-COOH、-CONH2 或-OC-O-CO-R2,必要时将得到的产物脱水。R'为正戊基、2-甲基丁基、3-甲基丁基、2,2-二甲基丙基、环丙基、环丁基、环戊基或环己基甲基的起始化合物在以前的文献中没有描述过,它们是通过式 R1NHCONH2 的化合物与氰基乙酸反应制备的、将生成的 1-氰基乙酰基-3-R1脲与碱环化,将生成的 1-R'-6-氨基脲嘧啶与 HNO2 硝化,并将生成的 1-R1-5-亚硝基-6-氨基脲嘧啶与 H2//PtO2 还原。